A reverse merger between troubled Threshold Pharmaceuticals Inc. and privately held Molecular Templates Inc. will take the latter company, focused on new a class of cancer drugs with potential in immuno-oncology, public. However, the combined company remains committed to the former's evofosfamide, which was considered dead and buried after a pair of Phase III failures in late 2015.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?